Author Topic: (JAMA) Association of sustained immunotherapy w/disability outcomes in active SPMS  (Read 9 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
These researchers are saying that even persons with SPMS might benefit from the disease-modifying drugs.  The study (link below) includes this statement:


Quote
Although this intraindividual variability in disease course makes any individual prognosis difficult, it also offers the possibility that MS with sufficient episodic inflammatory activity remains modifiable with immunotherapy at any stage of disease.


From JAMA Neurology (July 27, 2020), "Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis":



https://bit.ly/2X1lHnI
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
51 Views
Last post August 06, 2018, 12:36:14 pm
by agate
1 Replies
55 Views
Last post January 18, 2019, 12:03:47 pm
by agate
0 Replies
50 Views
Last post March 13, 2019, 02:56:48 pm
by agate
4 Replies
83 Views
Last post November 21, 2019, 07:14:23 am
by agate
0 Replies
17 Views
Last post January 29, 2020, 09:35:32 pm
by agate